EMA Authorised: Retacrit (epoetin zeta) — Pfizer Europe MA EEIG

View source ↗

Summary

Authorised status for Retacrit (epoetin zeta) by EMA for use in anemia-related indications, including kidney failure, cancer-related anemia, and autologous bloo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cancer
• Kidney Failure Chronic

Drugs mentioned

• RETACRIT (EPOETIN ALFA-EPBX)

Snippet

Status: Authorised. Therapeutic area: Anemia;Blood Transfusion, Autologous;Kidney Failure, Chronic;Cancer. MAH: Pfizer Europe MA EEIG. Decision date: 20/07/2026